This is a U.S. news story, published by USA Today, that relates primarily to Novo Nordisk news.
For more U.S. news, you can click here:
more U.S. newsFor more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from USA Today, you can click here:
more news from USA TodayOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
insulin shortages. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest new insulin news, NovoLog insulin news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
insulin supply shortagesUSA Today
•
73% Informative
Patients who depend on insulin have encountered shortages, delays and red tape from drug companies and pharmacies.
About 2 million Americans with Type 1 diabetes must take insulin to regulate their blood sugar because their bodies do not produce insulin.
About 38 million Americans have diabetes, the majority Type 2 .
Patients increasingly turn to drugs such as Ozempic and Mounjaro for weight loss.
In response to public pressure, manufacturers slashed insulin prices by 70% or more last year .
Companies have been questioned over the price of insulin in congressional hearings and investigations.
Advocates worried diabetes patients might not always be able to get the medication they need to survive.
GLP-1 diabetes and weight loss drugs tested their manufacturing capacity.
Novo Nordisk charges U.S. residents $ 969 a month for Ozempic, far more than what the drug costs in Canada or Europe .
CEO: "The world market for insulin is actually declining, so there's less demand" Smith: Diabetes patients especially those with Type 1 still need insulin.
VR Score
80
Informative language
83
Neutral language
55
Article tone
informal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links